Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone? - Top-Institutions - MDSpire

Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone?

  • By

  • Rus Prelog, Polona

  • Zupan, Matija

  • Kovacic, Alenka

  • Frol, Senta

  • Gregoric Kramberger, Milica

  • May 4, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    NYU Langone Health – Alzheimer’s Disease Research Center
    NYU Langone Health – Alzheimer’s Disease Research Center

    New York, New York

    Key Differentiators

    • Alzheimer's Disease
    • Cognitive Neurology

  • #2

    Mayo Clinic – Alzheimer’s Disease Research Center
    Mayo Clinic – Alzheimer’s Disease Research Center

    Rochester, Minnesota

    Key Differentiators

    • Alzheimer's Disease
    • Dementia Research

Original Source(s)

Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone?

  • by Rus Prelog, Polona , Zupan, Matija , Kovacic, Alenka , Frol, Senta , Gregoric Kramberger, Milica

  • May 4, 2026

Related Content

Advancing Alzheimer Disease Prediction With Large Language Model–Based Linguistic Feature Analysis: Development and Validation Study

ARPA-H Launches New Program to Deliver Rigorous, Gold-Standard Research Faster

The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease